Company intelligence / Profile preview

Haihua Life

Qingdao, Shandong, China

Ownership: Private
Development stage: Other

Overview

Haihua Biology is a Chinese biotechnology company specializing in the development of innovative vaccines and therapeutic biologics for infectious diseases. The company gained significant attention for its development of a nasal spray COVID-19 vaccine based on a Newcastle disease virus (NDV) vector platform. Beyond human health, Haihua Biology also maintains a strong presence in the veterinary medicine sector, developing vaccines for livestock and poultry. The company integrates research, development, and production to address global public health challenges through needle-free delivery technologies.

Therapeutic areas: Infectious Diseases
Modalities: VaccineBiologicViral vector
Industry: Biotech

Partnerships

China Agricultural University

Beyond the preview

Go deeper on Haihua Life.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Haihua Life.

Explore the full profile